• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向P-糖蛋白功能、p53和能量代谢:二甲双胍与2-脱氧葡萄糖联合使用可逆转MCF-7/Dox细胞对阿霉素的多药耐药性。

Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.

作者信息

Xue Chaojun, Wang Changyuan, Sun Yaoting, Meng Qiang, Liu Zhihao, Huo Xiaokui, Sun Pengyuan, Sun Huijun, Ma Xiaodong, Ma Xiaochi, Peng Jinyong, Liu Kexin

机构信息

Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.

Department of Pharmacy, Hebei General Hospital, Shijiazhuang, China.

出版信息

Oncotarget. 2017 Jan 31;8(5):8622-8632. doi: 10.18632/oncotarget.14373.

DOI:10.18632/oncotarget.14373
PMID:28052008
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5352427/
Abstract

Multidrug resistance(MDR) is a major obstacle to efficiency of breast cancer chemotherapy. We investigated whether combination of metformin and 2-deoxyglucose reverses MDR of MCF-7/Dox cells and tried to elucidate the possible mechanisms. The combination of metformin and 2-deoxyglucose selectively enhanced cytotoxicity of doxorubicin against MCF-7/Dox cells. Combination of the two drugs resumed p53 function via inhibiting overexpression of murine doubleminute 2(MDM2) and murine doubleminute 4(MDM4) leading to G2/M arrest and apoptosis in MCF-7/Dox cells. Combination of the two drugs had no effect on P-glycoprotein mRNA expression and P-glycoprotein ATPase activity but increased doxorubicin accumulation in MCF-7/Dox cells. The increased doxorubicin accumulation maybe associate with metabolic stress. Combination of metformin and 2-deoxyglucose initiated a strong metabolic stress in MCF-7/Dox cells via inhibiting glucose uptake, lactate, fatty acid, ATP production and protein kinase B(AKT)/ mammalian target of rapamycin(mTOR) pathway. Taken together, combination of metformin and 2-deoxyglucose reverses MDR of MCF-7/Dox cells by recovering p53 function and increasing doxorubicin accumulation. Furthermore, doxorubicin selectively increases MCF-7/Dox apoptosis via aggravating metabolic stress induced by metformin plus 2-deoxyglucose. The mutually reinforcing effect made the combination of metformin and 2DG had a better effect on reversing MDR.

摘要

多药耐药(MDR)是乳腺癌化疗疗效的主要障碍。我们研究了二甲双胍和2-脱氧葡萄糖联合使用是否能逆转MCF-7/Dox细胞的多药耐药性,并试图阐明其可能的机制。二甲双胍和2-脱氧葡萄糖联合使用选择性地增强了阿霉素对MCF-7/Dox细胞的细胞毒性。两种药物联合使用通过抑制小鼠双微体2(MDM2)和小鼠双微体4(MDM4)的过表达恢复p53功能,导致MCF-7/Dox细胞G2/M期阻滞和凋亡。两种药物联合使用对P-糖蛋白mRNA表达和P-糖蛋白ATP酶活性没有影响,但增加了阿霉素在MCF-7/Dox细胞中的蓄积。阿霉素蓄积增加可能与代谢应激有关。二甲双胍和2-脱氧葡萄糖联合使用通过抑制葡萄糖摄取、乳酸、脂肪酸、ATP生成以及蛋白激酶B(AKT)/雷帕霉素靶蛋白(mTOR)途径在MCF-7/Dox细胞中引发强烈的代谢应激。综上所述,二甲双胍和2-脱氧葡萄糖联合使用通过恢复p53功能和增加阿霉素蓄积来逆转MCF-7/Dox细胞的多药耐药性。此外,阿霉素通过加重二甲双胍加2-脱氧葡萄糖诱导的代谢应激选择性地增加MCF-7/Dox细胞凋亡。这种相互增强的作用使得二甲双胍和2-脱氧葡萄糖联合使用在逆转多药耐药方面具有更好的效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8615/5352427/7b516e88b29d/oncotarget-08-8622-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8615/5352427/fdd0f20f6c75/oncotarget-08-8622-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8615/5352427/4fbaf9bf0560/oncotarget-08-8622-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8615/5352427/0a36da850580/oncotarget-08-8622-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8615/5352427/0cf2bdacea21/oncotarget-08-8622-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8615/5352427/7b516e88b29d/oncotarget-08-8622-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8615/5352427/fdd0f20f6c75/oncotarget-08-8622-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8615/5352427/4fbaf9bf0560/oncotarget-08-8622-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8615/5352427/0a36da850580/oncotarget-08-8622-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8615/5352427/0cf2bdacea21/oncotarget-08-8622-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8615/5352427/7b516e88b29d/oncotarget-08-8622-g005.jpg

相似文献

1
Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.靶向P-糖蛋白功能、p53和能量代谢:二甲双胍与2-脱氧葡萄糖联合使用可逆转MCF-7/Dox细胞对阿霉素的多药耐药性。
Oncotarget. 2017 Jan 31;8(5):8622-8632. doi: 10.18632/oncotarget.14373.
2
Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.靶向P-糖蛋白表达与癌细胞能量代谢:二甲双胍与2-脱氧葡萄糖联合使用可逆转K562/Dox细胞对阿霉素的多药耐药性。
Tumour Biol. 2016 Jul;37(7):8587-97. doi: 10.1007/s13277-015-4478-8. Epub 2016 Jan 6.
3
Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.柴胡皂苷D可诱导乳腺癌MCF-7/阿霉素细胞中P-糖蛋白介导的多药耐药性的逆转。
Pathol Res Pract. 2017 Jul;213(7):848-853. doi: 10.1016/j.prp.2017.01.022. Epub 2017 Feb 3.
4
Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.五味子甲素通过抑制 P65 和 Stat3 磷酸化逆转多柔比星耐药的人乳腺癌细胞系。
Breast Cancer. 2018 Mar;25(2):233-242. doi: 10.1007/s12282-017-0821-9. Epub 2017 Nov 27.
5
Targeting Cellular Metabolism Chemosensitizes the Doxorubicin-Resistant Human Breast Adenocarcinoma Cells.靶向细胞代谢可使耐阿霉素的人乳腺腺癌细胞对化疗敏感。
Biomed Res Int. 2015;2015:453986. doi: 10.1155/2015/453986. Epub 2015 Oct 19.
6
Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.白藜芦醇通过增加阿霉素的细胞内流入量来增强其对多药耐药性人乳腺癌细胞的化学敏感性。
Biochim Biophys Acta. 2014 Jan;1840(1):615-25. doi: 10.1016/j.bbagen.2013.10.023. Epub 2013 Oct 24.
7
Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.β-榄香烯对多柔比星耐药乳腺癌细胞内 d-荧光素钾盐(ABC 底物)转运动力学的影响及其相关分子机制。
Eur J Pharm Sci. 2018 Jul 30;120:20-29. doi: 10.1016/j.ejps.2018.04.037. Epub 2018 Apr 25.
8
Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.阿尔及利亚蜂胶通过直接抑制P-糖蛋白外排泵、诱导G0/G1期细胞周期阻滞和凋亡来逆转人肺腺癌化疗耐药细胞(A549/DOX)的多药耐药性
Anticancer Agents Med Chem. 2018;18(9):1330-1337. doi: 10.2174/1871520618666180808100800.
9
Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.奈非那韦针对多种耐药机制,以提高阿霉素在MCF-7/Dox乳腺癌细胞中的疗效。
Biochimie. 2016 May;124:53-64. doi: 10.1016/j.biochi.2016.01.014. Epub 2016 Feb 1.
10
Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.多柔比星和二甲双胍共包封于聚(丙交酯-乙交酯)-d-α-生育酚聚乙二醇 1000 琥珀酸酯纳米粒中逆转多药耐药。
Pharm Res. 2018 Apr 18;35(6):119. doi: 10.1007/s11095-018-2404-7.

引用本文的文献

1
p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act.p53 在多柔比星诱导的心脏毒性和耐药性之间的十字路口:营养平衡的作用。
Nutrients. 2023 May 10;15(10):2259. doi: 10.3390/nu15102259.
2
GBM Cells Exhibit Susceptibility to Metformin Treatment According to TLR4 Pathway Activation and Metabolic and Antioxidant Status.根据Toll样受体4(TLR4)信号通路激活以及代谢和抗氧化状态,胶质母细胞瘤(GBM)细胞对二甲双胍治疗敏感。
Cancers (Basel). 2023 Jan 18;15(3):587. doi: 10.3390/cancers15030587.
3
Baicalein sensitizes triple negative breast cancer MDA-MB-231 cells to doxorubicin via autophagy-mediated down-regulation of CDK1.

本文引用的文献

1
Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.基于小肽对突变型p53蛋白构象稳定作用的癌症治疗方法。
Oncotarget. 2016 Mar 15;7(11):11817-37. doi: 10.18632/oncotarget.7857.
2
Repeated PM2.5 exposure inhibits BEAS-2B cell P53 expression through ROS-Akt-DNMT3B pathway-mediated promoter hypermethylation.反复暴露于细颗粒物2.5通过活性氧-蛋白激酶B-DNA甲基转移酶3B通路介导的启动子高甲基化抑制BEAS-2B细胞中P53的表达。
Oncotarget. 2016 Apr 12;7(15):20691-703. doi: 10.18632/oncotarget.7842.
3
Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK.
黄芩素通过自噬介导的 CDK1 下调使三阴性乳腺癌 MDA-MB-231 细胞对阿霉素敏感。
Mol Cell Biochem. 2023 Jul;478(7):1519-1531. doi: 10.1007/s11010-022-04597-9. Epub 2022 Nov 21.
4
P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease.P-糖蛋白:关于其结构、生理功能、调节及疾病中的改变的新见解
Heliyon. 2022 Jun 22;8(6):e09777. doi: 10.1016/j.heliyon.2022.e09777. eCollection 2022 Jun.
5
Metformin and Breast Cancer: Where Are We Now?二甲双胍与乳腺癌:我们现在处于什么阶段?
Int J Mol Sci. 2022 Feb 28;23(5):2705. doi: 10.3390/ijms23052705.
6
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance.细胞凋亡失调与癌症多药耐药性的发展
Cancers (Basel). 2021 Aug 28;13(17):4363. doi: 10.3390/cancers13174363.
7
Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells.二甲双胍增强尼罗替尼对慢性髓系白血病细胞的细胞毒性作用并克服尼罗替尼耐药性。
Korean J Intern Med. 2021 Mar;36(Suppl 1):S196-S206. doi: 10.3904/kjim.2019.336. Epub 2020 Apr 3.
8
Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer.二甲双胍:花中的癌症答案?二甲双胍作为乳腺癌抗癌剂的当前知识和未来前景。
Biomolecules. 2019 Dec 9;9(12):846. doi: 10.3390/biom9120846.
9
Reversal of obesity-driven aggressiveness of endometrial cancer by metformin.二甲双胍逆转肥胖驱动的子宫内膜癌侵袭性。
Am J Cancer Res. 2019 Oct 1;9(10):2170-2193. eCollection 2019.
10
Sorcin: a novel potential target in therapies of cancers.索辛蛋白:癌症治疗中的一种新型潜在靶点。
Cancer Manag Res. 2019 Aug 5;11:7327-7336. doi: 10.2147/CMAR.S208677. eCollection 2019.
二甲双胍和AICAR通过JNK途径在HepG2细胞中独立于AMPK调节NANOG表达。
Tumour Biol. 2016 Aug;37(8):11199-208. doi: 10.1007/s13277-016-5007-0. Epub 2016 Mar 3.
4
Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.在肝硬化大鼠模型中,二甲双胍通过抑制肝祖细胞激活来预防肝细胞癌的发生。
Cancer. 2016 Apr 15;122(8):1216-27. doi: 10.1002/cncr.29912. Epub 2016 Feb 23.
5
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.通过小分子MDM2拮抗剂Nutlin-3a靶向p53-MDM2相互作用:成人费城染色体阳性急性淋巴细胞白血病患者的一种新的挑战性靶向治疗方法。
Oncotarget. 2016 Mar 15;7(11):12951-61. doi: 10.18632/oncotarget.7339.
6
Energy disruptors: rising stars in anticancer therapy?能量干扰剂:抗癌治疗中的后起之秀?
Oncogenesis. 2016 Jan 18;5(1):e188. doi: 10.1038/oncsis.2015.46.
7
Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.靶向P-糖蛋白表达与癌细胞能量代谢:二甲双胍与2-脱氧葡萄糖联合使用可逆转K562/Dox细胞对阿霉素的多药耐药性。
Tumour Biol. 2016 Jul;37(7):8587-97. doi: 10.1007/s13277-015-4478-8. Epub 2016 Jan 6.
8
p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.p53 过表达增加多药耐药骨肉瘤细胞系的化疗敏感性。
Cancer Chemother Pharmacol. 2016 Feb;77(2):349-56. doi: 10.1007/s00280-015-2944-z. Epub 2015 Dec 23.
9
TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value.非小细胞肺癌中TP53和MDM2基因改变:评估其预后和预测价值。
Crit Rev Oncol Hematol. 2016 Mar;99:63-73. doi: 10.1016/j.critrevonc.2015.11.019. Epub 2015 Nov 28.
10
Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein.药物与蛋白质的氢键作用调控多药转运蛋白P-糖蛋白的ATP水解抑制作用。
Biochem Pharmacol. 2016 Feb 1;101:40-53. doi: 10.1016/j.bcp.2015.12.007. Epub 2015 Dec 11.